- BCIRG-005* either arm with G-CSF at the discretion of the investigator; CMF** patients in all arms received three cycles of CMF that were given every 4 weeks as oral cyclophosphamide at 100 mg/m2 on days 1–14 and intravenous methotrexate at 40 mg/m2 plus intravenous 5-fluorouracil at 600 mg/m2 on day 1 and day 8; CMF# intensified CMF (cyclophosphamide at 840 mg/m2, methotrexate at 57 mg/m2, and 5-fluorouracil at 840 mg/m2); NSABP B-38## all patients receive primary prophylaxis with pegfilgrastim or filgrastim; NR no report; A doxorubicin; E epirubicin; C cyclophosphamide; T docetaxel; P paclitaxel
